BD (Becton, Dickinson and company) has definitively agreed to acquire Bard for US$317 per common share in cash and stock, for a total consideration of $24 billion.
The agreement has been unanimously approved by the Boards of Directors of both companies.
Vince Forlenza, BD’s chairman and chief executive officer, says, “Combining with Bard will accelerate our ability to offer more comprehensive, clinically relevant solutions to customers and patients around the globe, creating a strong partner for healthcare providers who are increasingly focused on delivering better outcomes at a lower total cost.”
Tim Ring, Bard’s chairman and chief executive officer, says, “We are confident that this combination will deliver meaningful benefits for customers and patients as we see opportunities to leverage BD’s leadership, especially in medication management and infection prevention.”
